Comstock Mining Inc (NYSE: LODE) and Resverlogix Corp (TSX: RVX), lead the top small cap stock gainers for various sectors on both sides of the border, including one that saw its share price surge 54%.
Top U.S. Gainer
|
Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
Comstock Mining Inc |
NYSE |
LODE |
85.5 |
1.00 |
145,452 |
17.65% |
18.9% |
2.08 |
0.61 |
Comstock Mining Inc (NYSE: LODE), a gold and silver mining company with contiguous property in the Comstock and Silver City mining districts (collectively, the Comstock District), was the top performer in the U.S. diversified mining sector after gaining 17.6% and closed at $1.00 Thursday, while recording significant trading volumes of 145,452 shares. It also broke its key technical resistance level of 50-Day DMA at $0.94. Recently, the company has agreed to license an initial five metric tons of gold (or gold-equivalent) of validated, measured, and indicated resources to support the value of the initial 50 Million HOPE Gold Coins being sold. During the past 5-trading sessions, LODE gained 18.9% with daily average trading volumes of 119,210 shares, while the stock accumulated 29.8% gain during the past one month with daily average trading volumes of 215,075 shares. The stock is up 31.5% year-to-date.
1-Year Price Chart
Top Canadian Gainer
|
Company Name |
Exchange |
Ticker |
Market Cap |
Last Price |
Last Volume |
Price Return |
Price Return |
52-Week High |
52-Week Low |
|
Resverlogix Corp |
TSX |
RVX |
60.6 |
0.71 |
208,867 |
54.35% |
46.3% |
0.89 |
0.41 |
Resverlogix Corp (TSX: RVX), a Canada-based, clinical stage cardiovascular company, engaged in developing RVX-208, a small molecule for the treatment of atherosclerosis. RVX was the top sector gainer after climbing 54.35% and closed at C$0.71 Thursday, while recording significant trading volumes of 208,867 shares. It also broke its key technical resistance level of 30-Day, 50-Day and 200-Day DMA at C$0.49, C$0.53 and C$0.67 respectively. Recently, the company has presented at the 7th Annual Biotech Showcase Conference 2015 during JP Morgan week and shared developments of the company’s proposed new phase 3 clinical trial BETONMACE. During the past 5-trading sessions, RVX rose by 46.3% with daily average trading volumes of 69,359 shares, while the stock raised 61.3% during the past one month with daily average trading volumes of 46,270 shares. The stock is up 39.2% year-to-date.
1-Year Price Chart
